The group wants to improve on its own Welireg in a new phase 3 trial.
ApexOnco Front Page
Recent articles
Replimune gets a second chance, while Sarclisa could go subcutaneous.
GEN1286 looks dead, though MCLA-129 continues for now.
And the company says it won’t need to carry out another trial.
Takeda picked up IBI363 for $1.2bn, and now Innovent advances IBI3026.
A fresh licensing deal tidies up years of work between the two companies.
And that could affect the drug's third-line accelerated approval.
The “next-gen” PF-07985045 is gone, but the group has another pan-KRAS shot.
